Details of the Drug
General Information of Drug (ID: DMM86YK)
Drug Name |
4-(4-nitro-benzylideneamino)-benzenesulfonamide
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
CHEMBL255175; 66667-60-5; 4-[(1E)-2-(4-nitrophenyl)-1-azavinyl]benzenesulfonamide; AC1LBU0E; 4-[(4-nitrophenyl)methylideneamino]benzenesulfonamide; SCHEMBL12416808; CTK5I3043; CTK1J4461; DTXSID10340363; IJEQJCKQAKELNC-OQLLNIDSSA-N; MolPort-001-818-097; ZINC131032; BDBM50371746; STK790732; SBB006116; AKOS001719928; MCULE-1611993564; MCULE-9098092341; ST016439; EU-0084260; 4-(4-Nitrobenzylideneamino)Benzenesulfonamide; 4-[(4-Nitrobenzylidene)amino]benzenesulfonamide; Benzenesulfonamide, 4-(4-nitrobenzylidenamino)-
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 305.31 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 1.9 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 3 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 1 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 6 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||